Progerinin Therapy Offers Hope for Rare Progeria Disorder
A recent agreement between Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, and South Korea’s PRG S&T marks a significant step towards developing Progerinin, an oral drug aimed at treating Hutchinson-Gilford Progeria Syndrome (HGPS). This rare genetic disorder leads to accelerated ageing in children and remains one of the most severe paediatric conditions with no definitive cure so far. Understanding Hutchinson-Gilford Progeria Syndrome HGPS, commonly known as progeria, is an extremely rare genetic disease affecting approximately one in four million live births worldwide. Children with this condition appear normal at birth but begin to exhibit rapid ageing symptoms within the first two years. Despite severe physical deterioration, cognitive and motor development generally remain unaffected, making the disease particularly distressing. Genetic Basis and Disease Mechanism Progeria is caused by a mutation in the LMNA gene, which is responsible for producing lamin A, a p...